Results 141 to 150 of about 3,663 (172)

ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand

Journal of Clinical Lipidology, 2020
Yaling Han, Jiyan Chen, Shuyang Zhang
exaly  

Alirocumab induces plaque regression

Nature Reviews Cardiology, 2022
openaire   +2 more sources

Alirocumab

Reactions Weekly, 2019
openaire   +1 more source

Alirocumab

Reactions Weekly
openaire   +2 more sources

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events

Journal of the American College of Cardiology, 2019
Michael Szarek, Harvey D White, Gregory G Schwartz   +2 more
exaly  

Effect of Alirocumab on Mortality After Acute Coronary Syndromes

Circulation, 2019
Philippe Gabriel Steg, Michael Szarek, Marie-France Brégeault   +2 more
exaly  

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial

Journal of Clinical Lipidology, 2020
Eli M Roth, Christopher P Cannon, James M Mckenney   +2 more
exaly  

Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

Circulation: Cardiovascular Quality and Outcomes, 2019
Michael Szarek, Andrzej Budaj, Shaun G Goodman   +2 more
exaly  

ODYSSEY MONO: Effect of Alirocumab 75 Mg Subcutaneously Every 2 Weeks As Monotherapy Versus Ezetimibe Over 24 Weeks

Future Cardiology, 2015
Eli M Roth, James M Mckenney
exaly  

Alirocumab kommt wieder

MMW - Fortschritte der Medizin, 2021
openaire   +1 more source